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Abstract
Rationale—Neutrophilic airway inflammation plays a role in early structural lung disease in 
cystic fibrosis (CF), but the mechanisms underlying this pathway are incompletely understood.
Methods—Metabolites associated with neutrophilic inflammation were identified by discovery 
metabolomics on bronchoalveolar lavage fluid (BALF) supernatant from 20 preschool children 
(2.9±1.3 years) with CF. Targeted MS detection of relevant metabolites was then applied to 34 
children (3.5±1.5 years) enrolled in AREST CF who underwent chest CT and BAL from two 
separate lobes during 42 visits. Relationships between metabolites and localized structural lung 
disease were assessed using multivariate analyses.
Results—Discovery metabolomics identified 93 metabolites associated with neutrophilic 
inflammation, including pathways involved in metabolism of adenyl purines, amino acids and 
small peptides, cellular energy, and lipids. In targeted MS, products of adenosine metabolism, 
protein catabolism, and oxidative stress were associated with structural lung disease and predicted 
future bronchiectasis, and activities of enzymes associated with adenosine metabolism were 
elevated in the samples with early disease.
Conclusions—Metabolomics analyses revealed metabolites and pathways altered with 
neutrophilic inflammation and destructive lung disease. These pathways can serve as biomarkers 
and potential therapeutic targets for early CF lung disease.
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Take home message: Metabolomics in preschool children with cystic fibrosis reveals biomarkers that correlate with and predict early 
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Summary of findings: Increased activity of adenosine, amino acid, and other metabolic pathways predicts early cystic fibrosis lung 
disease
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Introduction
Although lungs from children with cystic fibrosis (CF) appear anatomically normal at birth 
[1], progressive airways disease can begin very early in life [2, 3]. Markers associated with 
neutrophilic inflammation, including IL-8 and neutrophil elastase, are correlated with the 
extent and progression of lung disease as quantified by CT [4], and the presence of 
detectable neutrophil elastase in airways of infants is predictive of later bronchiectasis [5]. 
These findings strongly suggest that neutrophilic inflammation plays a role in early disease, 
but the pathophysiological events involved in disease initiation and progression remain ill-
defined. Identifying these events is complicated by variable and heterogeneous nature of 
early CF lung disease that typically involves only a relatively small fraction of the lung [6].
The airway processes involved in early CF lung disease alter cell trafficking and metabolism, 
including airway surface metabolic pathways and accumulation of inflammatory cells within 
airway lumens that generate biologically active molecules [7–9]. This scenario suggests that 
metabolomics approaches, which attempt to characterize the full range of metabolites within 
biologic samples, can elucidate the pathophysiologic changes related to inflammation and 
structural disease. Indeed, previous metabolomics studies of airway secretions have 
demonstrated that neutrophilic airway inflammation in CF patients with established disease 
is characterized by increased concentrations of metabolites from several pathways, including 
those involved in cellular energy [10], protein catabolism [10, 11], adenyl purine metabolism 
[11], and lipid signaling molecules [12]. However, the relevance of these pathways to early 
disease has not been evaluated.
We hypothesized that metabolomics studies on airway secretions from young children with 
CF would identify the metabolic pathways associated with neutrophilic airway 
inflammation, and that these pathways would be predictive of early structural lung disease. 
To test these hypotheses, we performed mass spectrometric (MS) metabolomics on 
supernatants of bronchoalveolar lavage fluid (BALF) obtained during clinically indicated 
bronchoscopy in preschool children with CF to identify pathways associated with 
neutrophilic inflammation. We then studied relationships between identified metabolic 
pathways and early localized structural disease in a separate cohort of preschool children 
enrolled in AREST CF who underwent chest CT and lavage at a time of clinical stability. To 
address disease heterogeneity, BAL samples were obtained from two separate lobes and 
analyzed using statistical modeling to examine relationships between BALF metabolite 
concentrations and both current and future lobe specific CT scores.
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Methods
Subjects and samples
For discovery metabolomics, BALF from 20 preschool children with CF was collected 
during clinically indicated bronchoscopy at the University of North Carolina at Chapel Hill 
(UNC-CH) via standardized protocols [9] using one to three 10 cc/kg aliquots of sterile 
saline lavaged into the most visually affected lobe on each side. Return from both sides was 
combined and averaged 44±15% of lavaged volume. BALF aliquots were centrifuged at 
11,000×g for 5 minutes, and the supernatant stored at −80°C. Clinical data were abstracted 
from medical and research records. All children were fasted for >6 hours at the time of 
collection.
For comparison to structural lung disease, chest CT and BAL were performed on 34 children 
enrolled in AREST CF as described [2, 6] during 42 study visits (8 subjects were studied 
during 2 annual study visits). For BAL, the right middle lobe and the lingula were lavaged 
and the first aliquot from each side was processed separately, yielding two BAL aliquots per 
subject visit. BAL samples were centrifuged to remove cellular debris, and supernatants 
frozen at −80°C and shipped to UNC-CH on dry ice.
From the chest CT, each lung lobe was assessed for lobe specific bronchial wall thickening 
(BWT) and bronchiectasis (BE) using the modified CF-CT scoring system [2, 13] as well as 
PRAGMA-CF [14] to give continuous, lobe specific structural lung disease scores. Twenty 
nine CT images obtained from individual children one year following the BALF samples 
were also assessed to determine the predictive value of identified biomarkers.
Studies were approved by the UNC IRB (IRB#s 07-0787, 12-1538) and the Princess 
Margaret Hospital for Children, Perth and Royal Children’s Hospital, Melbourne, Ethics 
Committees (registration number 1762/EP)
MS Metabolomics
Metabolomic profiling was performed by Metabolon, Inc (Durham, NC). as previously 
described [15] using three independent platforms (ultra-high-performance liquid 
chromatography/tandem mass spectrometry for acidic and basic metabolites as well as gas 
chromatography/mass spectrometry). Metabolites were identified by automated comparison 
of ion features to a reference library. Values below limits of detection were imputed from the 
minimum detectable value. The average time between sample collection and analysis was 
290 days, with a range of 110–483 days.
Targeted MS
Targeted MS utilized a Quantum-Ultra triple quadrupole mass spectrometer (Thermo-
Finnigan, San Jose, CA) with chromatographic conditions similar to those previously 
described (UPLC T3 HSS C18 column, methanol/formic acid gradients [16]). BALF 
samples were spiked with isotopically labeled internal standard [17] and filtered through a 
10kDa size selection filter (EMD Millipore, Billerica, MA). Biomarker signals were defined 
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as ratios to the internal standard with the closest column run time. The average time between 
sample collection and analysis was 268 days, with a range of 39–473 days.
Adenosine metabolism—Adenosine metabolism in BALF was assessed by measuring 
hypoxanthine generated after incubating 5 µL BALF supernatant with 200 µM adenosine in 
50 µL Tris pH 7.5 at 37°C for one hour. Resulting hypoxanthine was assessed using a 
reaction mix containing Amplex red, horseradish peroxidase, and xanthine oxidase from the 
Xanthine Oxidase Fluorometric Assay Kit (Cayman Chemicals, Ann Arbor, MI). Signal was 
measured on a fluorometric plate reader with excitation 530 nM/absorbance 570 nM.
Statistical Analysis
MS signals from metabolomic data were analyzed using linear regression as well as 
Student’s T-test, with the false-discovery rate q-value used to correct for multiple 
comparisons. MS data were not normally distributed (by D’Agostino and Pearson omnibus 
normality test) and were log transformed prior to analysis. Categorical comparisons for 
demographic balance in discovery vs. validation samples were made using Fisher’s exact 
test. CF-CT scores were analyzed as binary outcomes of no disease (no BWT or BE) vs. 
disease (BWT or BE present). General estimating equations models (GEE) were fitted for 
each metabolite with Binomial family, logit link, robust standard errors and were adjusted 
for sex and batch/lung lobe interactions where appropriate. PRAGMA continuous CT 
outcomes (% Disease and % Bronchiectasis) were analyzed using hierarchical mixed effects 
models with random intercepts for each participant and random intercepts and slopes for 
each batch (as a function of metabolite), adjusted for sex. Predictive ability of metabolites 
was investigated by hierarchical mixed effects models described above and by plotting 
Receiver Operating Curves (ROCs) for presence of bronchiectasis at 12 months CT follow 
up. Area under the curves (AUCs) estimates and 95% confidence intervals were calculated 
using ROC regression adjusted for the lung lobe (right middle lobe or lingual) and 
PRAGMA % Bronchiectasis at baseline. Statistical analyses were performed using 
GraphPad Prism v5.0 (San Diego, CA) and Stata (version 13.0; StataCorp, College Station, 
TX, USA). Tukey boxplots are used for error bars and outliers.
Results
Discovery metabolomics was performed on BALF supernatants from 20 preschool children 
with CF undergoing clinically indicated bronchoscopy (Table 1). Persistent cough was the 
indication for most subjects (14/20), with evaluation of new Pseudomonas infection (3/20) 
or surveillance in conjunction with another procedure (3/20) less common indications. 
Respiratory pathogens were recovered from culture in 60% of samples, with Staphylococcus 
aureus and Pseudomonas aeruginosa most commonly identified (Table 1). Samples for 
metabolomics were chosen to reflect a range of airway inflammation, with 6 samples having 
neutrophilic bronchitis (% neutrophils ≥60%, >50,000 pathogens/mL on culture), 9 having 
no or mild bronchitis (% neutrophils <40%, ≤10,000 pathogens/mL on culture), and 5 
samples with intermediate values. A total of 152 metabolites were detected in at least one 
sample. Samples with greater airway neutrophilia had more overall MS signal, particularly 
those with % neutrophils >60% (Figure 1).
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Metabolites associated with neutrophilic inflammation were defined as those correlated with 
percent neutrophils at r>0.5 or that had >2-fold increases in signal in samples with 
bronchitis vs. those with no or mild bronchitis at a false discovery rate <0.05. This included 
93 metabolites that fell into four broad metabolic pathways (Table 2 and Supplemental Table 
1):
Adenyl purines and related metabolites
AMP was 4.7-fold elevated in airways with bronchitis (Table 2), but adenosine was reduced 
in bronchitic airways—the only metabolite in discovery metabolomics significantly 
decreased in the presence of bronchitis. In addition, the adenosine metabolites hypoxanthine 
and xanthine were 4.8 and 15.1 fold increased in BALF from bronchitic airways, 
respectively. The purine containing compound nicotinamide adenine dinucleotide (NAD) 
was also elevated in bronchitis, as were free nicotinamide and kynurenine, a tryptophan 
metabolite that serves as an intermediate in NAD synthesis.
Amino acids, small peptides, and related pathways
A large number of amino acids, dipeptides, and tripeptides were highly elevated (>10-fold) 
in airways with bronchitis, with correlation coefficients to % neutrophils often exceeding 0.7 
(Table 2). Similarly, bronchitic airways had higher concentrations of several metabolic 
products of amino acids, including N-acetylated derivatives of methionine, serine, and 
lysine. Higher concentrations oxidative products of the antioxidant peptide glutathione, 
including glutathione disulfide (GSSG) (2.5 fold increased) and cysteine-glutathione 
disulfide (9.0 fold increased), were also observed.
Arginine related signaling pathways were also implicated in the metabolomics analysis. 
Arginine, citrulline, and fumarate are involved in generating the signaling molecule nitric 
oxide [18], and all of these metabolites were elevated in bronchitic samples. Arginine can 
also be metabolized to ornithine, the initial substrate in synthesis of polyamines [19]. Both 
ornithine and the polyamine putrescine were elevated in bronchitis, as was free adenine 
generated primarily within the polyamine synthesis pathway [20].
Cellular energy metabolism
Several metabolites directly related to energy metabolism were found at higher 
concentrations in samples from bronchitic airways, including glycolytic and Kreb’s cycle 
metabolites (glucose, citrate, malate). Lactate was 4.1 fold increased, suggestive of 
anaerobic metabolism. Metabolites involved in fatty acid oxidation, including carnitine and 
acylcarnitine, were also elevated. Metabolomics also revealed elevated concentrations of 1,5-
anhydroglucitol in bronchitis, a compound that regulates glycemic control and has anti-
inflammatory properties [21].
Lipids
Several lipid metabolites were elevated in the presence of bronchitis, including both 
common cell membrane lipids (phosphoethanolamine, cholesterol) and those involved in 
signaling pathways (arachidonate, myo-inositol). Several lysolipids were also elevated in 
bronchitis.
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Metabolomic biomarkers and early structural lung disease
To determine relationships to early structural lung disease, we developed targeted MS 
methods for a subset of 28 metabolomic biomarkers amenable to MS detection using 
previously established methods [11, 16] including amino acids, dipeptides, adenyl purines, 
nicotinamide, polyamines, glutathione and glutathione disulfide (oxidized glutathione), as 
well as urea as a potential dilution marker (Supplemental Table 1). This biomarker panel was 
then applied to a validation set of samples from 34 preschool children enrolled in AREST 
CF during 42 study visits (8 longitudinally sampled subjects). In contrast to the subjects in 
the discovery set, bronchoscopy and chest CT in AREST CF are performed at a time of 
clinical stability, as evidenced by lower neutrophil counts and fewer recovered pathogens 
compared to our discovery dataset (Table 1). Heterogeneity of early CF lung disease was 
addressed by obtaining BALF independently from two separate lobes (right middle lobe and 
lingua) at each study visit and using lobe specific chest CT scores for analysis.
Metabolomic biomarkers and inflammatory markers
Conventional inflammatory markers including cell counts and IL-8 were measured in 
samples from the right middle lobe in all subjects (n=42). Analyses revealed significant 
negative associations (coefficients [95% confidence interval]) between BAL neutrophil 
counts (% of total cell count) and adenosine (−0.376 [−0.569, −0.184]) and glutathione 
(−0.285 [−0.419, −0.150]). Significant positive associations were found between neutrophils 
and inosine (0.220 [0.042, 0.399]) and ornithine (0.017 [0.008, 0.025]). For IL-8, a 
significant negative association was found to glutathione (−0.137 [−0.266, −0.007]), with 
significant positive associations to inosine (0.365 [0.227, 0.503]), leucine (0.071 [0.004, 
0.139]), ornithine (0.012 [0.004, 0.020]) and spermidine (0.010 [0.005, 0.016]). No 
significant associations were observed between any metabolomic biomarker and neutrophil 
elastase, though these analyses were limited by the fact that neutrophil elastase was detected 
in only 5 of 42 samples.
Metabolomic biomarkers and structural lung disease
Statistical modeling was utilized to assess relationships between various metabolites and 
lobe specific structural lung disease using both dichotomous variables (presence/absence of 
disease) and the PRAGMA continuous scoring system. Lobes with structural lung disease 
(bronchial wall thickening [BWT] as a marker of early disease or bronchiectasis [BE] as a 
marker of later disease) had lower concentrations of adenosine; odds ratio (OR = 0.32, 
p<0.001, Figure 2, Table 3) than samples from lobes without BWT or BE. Trends towards 
increases in the downstream adenosine metabolites hypoxanthine (OR = 2.32, p=0.203) and 
xanthine (OR = 2.30, p=0.197) were also observed. Glutathione was significantly reduced in 
lobes with structural disease (OR = 0.40, p<0.01), as was oxidized glutathione (OR = 0.16, 
p<0.01). Associations between amino acids and structural lung disease were not statistically 
significant, but the Leu-Pro dipeptide was strongly elevated in lobes with structural lung 
disease (OR>100, p<0.001).
Using lobe specific PRAGMA disease scores, we observed negative correlations for both 
adenosine (β = −0.74, p=0.014) and glutathione (β = −0.82, p=0.008) (Table 3). In contrast, 
positive correlations were observed for the adenosine metabolites hypoxanthine (β = 0.93, 
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p=0.003) and xanthine (β = 1.46, p<0.001) as well as the amino acids phenylalanine, 
tyrosine, and the Leu-Pro dipeptide (β = 2.14, 2.13, 2.16 respectively, p<0.001 for all). 
Similar findings were observed for bronchiectasis specific PRAGMA scores (Table 3).
Predictive power of metabolomic biomarkers
Hierarchical mixed effects models and ROCs were utilized to assess the ability of 
metabolites to predict development of new bronchiectasis at the next annual visit, using data 
available in 29 children. Metabolites predictive of future bronchiectasis included 
hypoxanthine (β1 = 0.19 [0.06, 0.31]; p=0.003), phenylalanine (β1 = 0.27 [0.11, 0.43]) and 
Leu-Pro (β1 = 0.17 [0.01, 0.33]). Each of these metabolites was a better predictor of 
bronchiectasis than neutrophil elastase (β1 = 0.08 [0.00, 0.16]), a known biomarker of early 
CF lung disease (Figure 3) [5].
Early structural lung disease and adenosine metabolism
These analyses suggested an association between early lung disease and activity of the 
adenosine metabolic pathway, in which adenosine is converted to uric acid through the 
actions of adenosine deaminase, purine nucleotide phosphorylases, and xanthine oxidase. To 
assess these activities directly, we measured adenosine metabolism in BALF supernatants. 
BALF samples from children with significant bronchitis, but not those without bronchitis, 
metabolized adenosine to hypoxanthine (Figure 4), indicating elevated activities of 
adenosine deaminase and purine phosphorylase. AREST CF samples from lobes with 
bronchiectasis also had significant adenosine metabolic activity. Xanthine oxidase activity in 
these samples was not detected (not shown).
Discussion
Using metabolomics, we identified several metabolites and metabolic pathways altered in 
the presence of neutrophilic airway inflammation in young children with CF, including those 
involving adenyl purines, amino acids and peptides, cellular energy, and lipids. Several of 
these pathways, including those related to adenosine metabolism, oxidative stress, and 
protein catabolism, were strongly associated with structural lung disease. Although many of 
these pathways are also altered in older children [10, 11], this study demonstrates that these 
metabolic changes occur early in the disease process before the onset of permanent 
structural lung damage. These pathways represent potential therapeutic targets, and the 
relevant metabolites are biomarkers of patients at risk for developing bronchiectasis.
The adenosine metabolic pathway in particular appears altered early and predictive of future 
disease. Adenosine plays an important and complex role in modulating signaling responses 
to inflammation [22], with both pro and anti-inflammatory properties, though normal airway 
adenosine concentrations are thought to be anti-inflammatory [22, 23]. The decreased 
adenosine and elevated adenosine metabolic activity likely increase airway inflammatory 
responses, and the metabolic products hypoxanthine and xanthine contribute to oxidative 
stress through metabolism by xanthine oxidase, which generates oxygen superoxides [24, 
25].
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Increased oxidative stress in early disease is consistent with the observed reduction in 
glutathione, the primary antioxidant in the airway [26]. Decreased lower airway glutathione 
concentrations have been observed in preschool children with CF [27], although our study is 
the first to demonstrate a relationship to structural lung disease. Our ability to detect these 
relationships likely reflects our use of lobe specific lavages and CT scores to account for 
disease heterogeneity. Somewhat surprisingly, the concentrations of oxidized glutathione 
were also reduced in the AREST CF samples, though we suspect this may reflect an 
inability to preserve the oxidative state on storage and transport of these samples.
These findings suggest that drugs that affect the adenosine metabolism are potential 
therapeutic targets in CF. Such drugs could represent “low hanging fruit,” since several 
relevant pharmaceuticals are approved or in late stage clinical trials. For example, inhibitors 
of purine nucleoside phosphorylase that block hypoxanthine formation [28] are in clinical 
trials for gout. Also, the xanthine oxidase inhibitor febuxostat was recently approved for 
gout [29] but has also been shown to reduce airway inflammation in an animal model of 
acute lung injury [30]. Although we did not detect xanthine oxidase activity in BALF 
supernatant, the high concentrations of xanthine and uric acid (metabolic products of 
xanthine oxidase) in the airway samples indicate that this enzyme is active in vivo, likely 
restricted to the airway epithelial cell surface. Indeed, our adenosine metabolism studies may 
underestimate total activity since we could only assess soluble activities and not the 
contribution from enzymes found on airway surfaces.
The strong associations between amino acids and dipeptides with early disease are 
consistent with increased activity of proteases such as neutrophil elastase. These findings are 
supportive of previous studies identifying airway proteases as potential therapeutic targets in 
early CF lung disease [5]. Notably, the Leu-Pro dipeptide was more readily detected and 
more predictive than neutrophil elastase, suggesting that it and similar metabolomics 
biomarkers may be more sensitive indicators of protease activity.
Discovery metabolomics suggested that several arginine related signaling pathways are 
upregulated in the presence of airways inflammation. Increased concentrations of ornithine 
imply greater arginase activity in inflamed airways and are consistent with previously 
reported increases in CF sputum polyamines [19]. Since urea is another product of arginase 
activity, this relationship could impact the utility of urea as an airway dilution marker. 
Increased concentrations of citrulline and fumarate were also observed, suggesting greater 
flux through the nitric oxide (NO) synthesis pathway. However, exhaled NO is reportedly 
low in CF [31]. The reasons for this discrepancy are not clear.
In fact, several metabolites identified in our study have potential as biomarkers of early lung 
disease. Many of these metabolites are detectable by conventional methods and could 
potentially serve as indicators of at risk children that are more sensitive than the current gold 
standard of neutrophil elastase [5]. In addition, some of the metabolic signatures observed in 
BALF are detectable in exhaled breath condensate (EBC) from young children [32, 33], 
offering the potential to develop a relatively non-invasive technique to identify children with 
early structural lung disease.
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There were several limitations that could affect our findings. All subjects were fasting at the 
time of bronchoscopy, and it is possible that metabolic patterns would differ in non-fasting 
individuals. We also did not assess the impact of treatment beyond an indirect effect of 
altering airway inflammation. Similarly, we were not able to determine the direct 
contribution of bacterial pathogens to the metabolomic signal. However, given the 
complexity of the CF airway microbiome [34], assessing the relative contributions of host 
vs. bacterial pathogens poses considerable challenges.
Another limitation is that we utilized percent neutrophils to define airway inflammation in 
our discovery metabolomic analysis. While airway neutrophils are a well-accepted marker of 
inflammation [8], this approach does have some shortcomings since increases in other cell 
counts (such as lymphocytes during an acute viral infection) or sampling issues could alter 
the relationship between percent neutrophils and airway inflammation. Similarly, neutrophil 
counts alone may not perfectly reflect their activity or propensity to cause airway damage. 
Nevertheless, we did observe associations between many of the metabolites and metabolic 
pathways identified by discovery metabolomics and other inflammatory markers as well as 
structural lung disease. These associations raise our confidence that our findings reflect early 
CF airways disease pathophysiology.
This study focused on metabolites amenable to our established MS methods, and we have 
not yet analyzed other metabolites identified by discovery metabolomics such as those 
involved in cellular energy and lipid metabolism. These metabolites will require different 
MS approaches for detection, but they offer fertile ground for further investigation.
In conclusion, MS metabolomics demonstrate that neutrophilic airway inflammation in 
young children with CF is associated with increased concentrations of metabolites from 
many pathways, several of which are predictive of current and future early structural lung 
disease. In particular, alterations in adenosine metabolism and resulting oxidative stress are 
linked to both bronchitis and structural lung disease and offer opportunities for noninvasive 
biomarker detection and serve as promising targets for therapeutic intervention.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Average MS metabolomics signal in BALF from 20 preschool children with CF plotted 
relative to % neutrophils on cell counts from these samples. Samples with >60% neutrophils 
had more overall MS signal.
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Figure 2. 
Metabolite concentrations for various metabolites in lobes with bronchial wall thickening 
(BWT), bronchiectasis (BE), or neither BWT or BE (None) by CF-CT scoring system. 
*=p<0.05 by multivariate analysis.
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Figure 3. 
ROC curves demonstrating the sensitivity and specificity for various metabolites relative to 
neutrophil elastase (NE, marked as ‘X’) in predicting future bronchiectasis. A. Purine 
metabolites adenosine (Ado, open circles) and hypoxanthine (Hyp, open triangles). B. 
Protein catabolism metabolites phenylalanine (Phe, filled circles) and the dipeptide Leu-Pro 
(filled triangles).
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Figure 4. 
Adenosine metabolic activity in BALF from preschool children with CF was assessed as the 
ability to generate hypoxanthine (Hyp) from exogenously added adenosine (Ado). Samples 
with no significant bronchitis (<40% neutrophils) had no significant activity, whereas 
activity was readily detected in samples with bronchitis (>60% neutrophils). BALF from 
clinically stable preschoolers with bronchiectasis (BE) on chest CT showed moderate levels 
of adenosine metabolic activity. N=3–4 per group. * = p<0.01 by Mann-Whitney, with 
significant post tests for bronchitis and BE groups relative to no bronchitis.
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Table 1
Subject Demographics
Discovery Set AREST CF Set
n (subjects) = 20 34
n (BALF) = 20 84
Age (years) 2.9±1.3 (0.48–4.95) 3.5±1.5 (0.96–5.83)
% Male 55% 43%
BMI (Z-score) 0.1±1.1 0.0±1.8
Treatment, hypertonic saline 6% 15%
Treatment, dornase alpha 3% 35%
Treatment, amoxicillin/clavulanate 48% 0%
Cell count (×106 cells/ml) 2.8±3.7 (0.18–12.94) 0.7±0.3 (0.06–1.67)
% PMNs 48.8±27.2 (2.5–93) 20.2±23.9 (0.67–92)
% with Pathogens 60% 17%
% with Staphylococcus 25% 7%
% with Pseudomonas 25% 2%
BALF = bronchoalveolar lavage fluid; PMNs = neutrophils
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Table 2
Selected metabolites related to neutrophilic airway inflammation in discovery metabolomics
Pathway Metabolite Corr %
PMNs
Ratio* Q-value
Adenyl purine metabolism
adenosine 5′-monophosphate (AMP) 0.60 4.7 0.040
adenosine −0.69 0.2 0.002
hypoxanthine 0.54 4.8 0.002
xanthine 0.76 15.1 0.000
urate 0.34 2.4 0.031
nicotinamide 0.45 3.2 0.006
nicotinamide adenine dinucleotide (NAD+) 0.63 3.5 0.022
kynurenine 0.65 2.5 0.016
Amino acids, dipeptides, and related metabolites
alanine 0.68 36.9 0.000
phenylalanine 0.74 36.2 0.000
tyrosine 0.75 44.1 0.000
leucine 0.37 5.4 0.058
isoleucine 0.61 6.6 0.002
methionine 0.60 2.7 0.005
serine 0.76 20.0 0.000
lysine 0.75 141.8 0.000
valine 0.76 43.6 0.000
aspartylleucine 0.78 29.6 0.000
aspartylphenylalanine 0.73 15.0 0.000
glycylleucine 0.73 33.9 0.000
lysylleucine 0.79 5.4 0.000
N-acetylmethionine 0.45 2.5 0.032
N-acetylserine 0.59 2.5 0.008
N6-acetyllysine 0.76 12.0 0.000
cysteine-glutathione disulfide 0.69 9.0 0.000
glutathione, oxidized (GSSG) 0.34 2.5 0.022
arginine 0.63 29.2 0.000
citrulline 0.79 24.3 0.000
fumarate 0.43 2.2 0.009
ornithine 0.75 71.7 0.000
putrescine 0.35 6.5 0.061
adenine 0.40 2.9 0.011
Cellular energy
glucose 0.65 9.2 0.002
citrate 0.66 4.1 0.009
malate 0.66 2.9 0.004
lactate 0.71 4.1 0.000
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Pathway Metabolite Corr %
PMNs
Ratio* Q-value
carnitine 0.43 3.2 0.009
acetylcarnitine 0.50 3.6 0.003
1,5-anhydroglucitol 0.81 7.0 0.000
Lipids
phosphoethanolamine 0.52 4.4 0.003
cholesterol 0.67 2.1 0.009
arachidonate (20:4n6) 0.64 9.2 0.003
myo-inositol 0.43 2.3 0.023
1-stearoylGPE1 0.68 2.5 0.030
2-arachidonoylGPE1 0.65 4.1 0.022
2-docosahexaenoylGPE1 0.66 2.7 0.009
2-oleoylGPE1 0.73 5.4 0.005
1GPE = glycerphosphoethanolamine
*
Ratio = ratio of metabolite concentrations in samples with bronchitis to those with no/mild bronchitis
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